Investor Relations

Eton Pharmaceuticals, Inc. is a commercial company focused on developing, acquiring, and commercializing high-potential therapies for the treatment of patients with rare diseases. We have a diversified pipeline of product candidates across multiple therapeutic areas, and a team with significant expertise in bringing products from clinical trials to patients with exceptional speed.

Volume :

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases
March 16, 2023
Q4 2022 revenue of $8.5 million Q4 Product sales and royalty revenue up 220% from prior year and 9% from Q3 Q4 positive net income Management to hold conference call today at 4:30pm ET DEER PARK, Ill. , March 16, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq:
March 15, 2023
-- Product is targeting rare pediatric endocrinology condition -- -- Potential for NDA submission in Q2 2024 -- DEER PARK, Ill. , March 15, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and
March 7, 2023
DEER PARK, Ill. , March 07, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter 2022 financial results on Thursday, March